Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency

Summary

Factor XIII (FXIII) is a fibrin-stabilising factor consisting of catalytic A subunits (FXIII-A) and carrier B subunits (FXIII-B). FXIII-B prevents the fast clearance of FXIII-A from the circulation. Congenital FXIII-A deficiency is a rare bleeding disorder, and congenital FXIII-B deficiency is even rarer. Through our recent nationwide survey on “acquired haemophilia-like disease due to anti-FXIII autoantibodies,” we newly diagnosed severe congenital FXIII-B deficiency in a Japanese man. He developed thrombocytopenia and gingival bleedings at the age of 73, and his FXIII activity was as low as 10% of the normal. When he suddenly developed spontaneous intramuscular haematoma, the bleeding was arrested by infusing FXIII concentrates. However, his FXIII activity remained around 10% of the normal. At the age of 74, ELISA and western blotting assay unexpectedly revealed complete absence of FXIII-B in the patient’s plasma. A dot blot assay detected anti-FXIII-B alloantibodies for the first time in this disease, which could be attributed to the infusion of exogenous FXIII. He was found to be homozygous for a Japanese founder-effect mutation of F13B. Repeated infusions of exogenous FXIII for hemostasis increased anti-FXIII-B alloantibodies that resisted FXIII substitution. To the best knowledge of the authors, none of the remaining 10 reported cases of congenital FXIII-B deficiency developed alloantibodies to exogenous FXIII-B of plasma FXIII. An originally mild bleeding phenotype of severe congenital FXIII-B deficiency can be exaggerated by additional acquired conditions. Physicians should consider congenital FXIII-B deficiency when they encounter cases of unexplained bleeding disorders.

Keywords

Factor concentrates - factor XIII/transglutaminases - inherited coagulation disorders - alloantibody - factor XIII-resistant state

^* These authors contributed equally to this study.

• References

• 1 Ichinose A. Extracellular transglutaminase: factor XIII. Prog Exp Tumor Res 2005; 38: 192-208.
• 2 Muszbek L, Bereczky Z, Bagoly Z. et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931-972.
• 3 Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14: 1190-1200.
• 4 Biswas A, Ivaskevicius V, Seitz R. et al. An update of the mutation profile of Factor 13 A and B genes. Blood Rev 2011; 25: 193-204.
• 5 Hashiguchi T, Saito M, Morishita E. et al. Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII. Blood 1993; 82: 145-150.
• 6 Koseki S, Souri M, Koga S. et al. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood 2001; 97: 2667-2672.
• 7 Izumi T, Hashiguchi T, Castaman G. et al. Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood 1996; 87: 2769-2774.
• 8 Souri M, Izumi T, Higashi Y. et al. A founder effect is proposed for factor XIII B subunit deficiency caused by the insertion of triplet AAC in exon III encoding the second Sushi domain. Thromb Haemost 1998; 80: 211-213.
• 9 Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-370.
• 10 Ivaskevicius V, Biswas A, Loreth R. et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 2010; 16: 675-682.
• 11 Lovejoy AE, Reynolds TC, Visich JE. et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
• 12 Ichinose A, Souri M. Japanese collaborative research group on “Acquired haemorrha-philia due to factor XIII deficiency”. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105: 925-927.
• 13 Ichinose A, Souri M. Reduced difference of α(2)-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Int J Hemato 2012; 95: 47-50.
• 14 Souri M, Kaetsu H, Ichinose A. Sushi domains in the B subunit of factor XIII responsible for oligomer assembly. Biochemistry 2008; 47: 8656-8664.
• 15 Ichinose A. Haemorrhagic acquired factor XIII (13) deficiency and acquired haemorrhaphilia 13 revisited. Semin Thromb Haemost 2011; 37: 382-388.
• 16 Lorand L, Urayama T, De Kiewiet JW. et al. Diagnostic and genetic studies on fibrin-stabilising factor with a new assay based on amine incorporation. J Clin Invest 1969; 48: 1054-1064.
• 17 Rodeghiero F, Tosetto A, Di Bona E. et al. Clinical pharmacokinetics of a placentaderived factor XIII concentrate in type I and type II factor XIII deficiency. Am J Hematol 1991; 36: 30-34.
• 18 Souri M, Koseki-Kuno S, Takeda N. et al. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol 2008; 87: 60-68.
• 19 Godal HC. An inhibitor to fibrin stabilising factor (FSF, factor XIII). Scand J Haematol 1970; 07: 43-48.
• 20 Godal HC, Ly B. An inhibitor of activated factor XIII, inhibiting fibrin cross-linking but not incorporation of amine into casein. Scand J Haematol 1977; 19: 443-438.
• 21 Heriksson P, McDonagh J, Villa M. Type I autoimmune inhibitor of factor XIII in a patient with congenital factor XIII deficiency. Thromb Haemost 1983; 50: 272.
• 22 Seiving B, Henriksson P, Stenberg P. et al. A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency. Br J Haematol 1992; 82: 414-416.
• 23 Manco-Johnson M, Nuss R, Lefkowitz J. et al. Characterisation and quantitation of an inhibitor to the A chain of Factor XIII (F XIII) in a child with severe factor XIII deficiency. Blood. 1993 82. Abstract 596a.
• 24 Huth-Kühne A, Lages P, Zimmermann R. Intracranial haemorrhage in a patient with congenital factor XIII deficiency and inhibitor - successful treatment with Ig-immunoadsorption and high dose continuous factor XIII infusion. Blood. 1998 92. Abstract 106b.
• 25 Rivard GE, St Louis J, Lacroix S. et al. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 09: 711-716.
• 26 Ajzner E, Schlammadinger A, Kerényi A. et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-725.
• 27 Yorifuji H, Anderson K, Lynch GW. et al. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988; 72: 1645-1650.